Research progress on radiation dose escalation for locally advanced non-small cell lung cancer
10.3760/cma.j.issn.1004-4221.2019.10.016
- VernacularTitle: 局部晚期非小细胞肺癌放疗剂量提升研究进展
- Author:
Daquan WANG
1
;
Nan BI
;
Lvhua WANG
Author Information
1. Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100021, China
- Publication Type:Review
- Keywords:
Lung neoplasm/radiotherapy;
Dose escalation;
Simultaneous integrated boost
- From:
Chinese Journal of Radiation Oncology
2019;28(10):788-791
- CountryChina
- Language:Chinese
-
Abstract:
RTOG 0617 trial has indicated that no benefit can be obtained in the overall survival of locally advanced non-small cell lung cancer patients by improving the prescribed dose, which promotes the adjustments to the strategies of dose escalation. Currently, multiple studies have been designed to explore more effective approaches to boost dose, such as dose boosts based on increased 18FDG-uptake regions, simultaneous integrated boost intensity-modulated radiotherapy and modulation of dose fractions, which have achieved a series of progress. The widespread application of PET-CT and intensity-modulated radiotherapy offers broad space for the dose escalation and optimization.
